CA3215582A1 - Cancer therapy using toll-like receptor agonists - Google Patents

Cancer therapy using toll-like receptor agonists

Info

Publication number
CA3215582A1
CA3215582A1 CA3215582A CA3215582A CA3215582A1 CA 3215582 A1 CA3215582 A1 CA 3215582A1 CA 3215582 A CA3215582 A CA 3215582A CA 3215582 A CA3215582 A CA 3215582A CA 3215582 A1 CA3215582 A1 CA 3215582A1
Authority
CA
Canada
Prior art keywords
administered
tlr9 agonist
dose
liver
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3215582A
Other languages
English (en)
French (fr)
Inventor
Steven C. Katz
Bryan F. COX
David Benjamin Jaroch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trisalus Life Sciences Inc
Original Assignee
Trisalus Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trisalus Life Sciences Inc filed Critical Trisalus Life Sciences Inc
Publication of CA3215582A1 publication Critical patent/CA3215582A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3215582A 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists Pending CA3215582A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169674P 2021-04-01 2021-04-01
US63/169,674 2021-04-01
US202263298589P 2022-01-11 2022-01-11
US63/298,589 2022-01-11
PCT/US2022/022801 WO2022212690A1 (en) 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists

Publications (1)

Publication Number Publication Date
CA3215582A1 true CA3215582A1 (en) 2022-10-06

Family

ID=83456830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3215582A Pending CA3215582A1 (en) 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists

Country Status (7)

Country Link
EP (1) EP4313315A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024512765A (cg-RX-API-DMAC7.html)
KR (1) KR20240004419A (cg-RX-API-DMAC7.html)
AU (1) AU2022249092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215582A1 (cg-RX-API-DMAC7.html)
DE (1) DE112022001882T9 (cg-RX-API-DMAC7.html)
WO (1) WO2022212690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121568740A (zh) * 2023-04-06 2026-02-24 特萨乐斯生命科学公司 用于提供局部湍流以递送医用栓塞剂的系统和装置

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US20040009151A1 (en) * 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7963956B2 (en) * 2003-04-22 2011-06-21 Antisense Pharma Gmbh Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
US8696698B2 (en) 2009-12-02 2014-04-15 Surefire Medical, Inc. Microvalve protection device and method of use for protection against embolization agent reflux
US8500775B2 (en) 2009-12-02 2013-08-06 Surefire Medical, Inc. Protection device and method against embolization agent reflux
US9539081B2 (en) 2009-12-02 2017-01-10 Surefire Medical, Inc. Method of operating a microvalve protection device
US9770319B2 (en) 2010-12-01 2017-09-26 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9968740B2 (en) 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
HUE053145T2 (hu) * 2014-12-31 2021-06-28 Checkmate Pharmaceuticals Inc Kombinált tumor immunterápia
US20160287839A1 (en) 2015-03-31 2016-10-06 Surefire Medical, Inc. Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
EP3302501B1 (en) * 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
CA3020873A1 (en) * 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
US10806893B2 (en) 2017-01-10 2020-10-20 Surefire Medical, Inc. Guiding catheter having shape-retentive distal end
US10588636B2 (en) 2017-03-20 2020-03-17 Surefire Medical, Inc. Dynamic reconfigurable microvalve protection device
US20190298983A1 (en) 2018-01-15 2019-10-03 Surefire Medical, Inc. Injection Port for Therapeutic Delivery
WO2019160866A2 (en) * 2018-02-13 2019-08-22 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy
US11850398B2 (en) 2018-08-01 2023-12-26 Trisalus Life Sciences, Inc. Systems and methods for pressure-facilitated therapeutic agent delivery
US12433597B2 (en) 2019-06-04 2025-10-07 Trisalus Life Sciences, Inc. Atraumatic occlusive system with compartment for measurement of vascular pressure change
US20220249389A1 (en) * 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
US12686870B2 (en) * 2020-01-10 2026-07-21 Sbi Biotech Co., Ltd. TLR9 agonists
AU2021347154A1 (en) * 2020-09-22 2023-05-11 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists

Also Published As

Publication number Publication date
JP2024512765A (ja) 2024-03-19
DE112022001882T9 (de) 2024-02-29
DE112022001882T5 (de) 2024-01-18
WO2022212690A1 (en) 2022-10-06
KR20240004419A (ko) 2024-01-11
AU2022249092A9 (en) 2023-10-26
AU2022249092A1 (en) 2023-10-12
EP4313315A1 (en) 2024-02-07
EP4313315A4 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
AU2016271018A1 (en) Combination of a PD-1 antagonist and CPG-C type oligonucleotide for treating cancer
US20230364125A1 (en) Cancer therapy using toll-like receptor agonists
US20240180952A1 (en) Cancer therapy using toll-like receptor agonists
AU2022249092A9 (en) Cancer therapy using toll-like receptor agonists
US20230374523A1 (en) Cancer therapy using toll-like receptor agonists
HK40107087A (en) Cancer therapy using toll-like receptor agonists
US20250101438A1 (en) Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists
HK40100192A (en) Cancer therapy using toll-like receptor agonists
HK40096714A (en) Cancer therapy using toll-like receptor agonists
CN116685330A (zh) 使用toll样受体激动剂的癌症疗法
US20240218068A1 (en) Cancer therapy using checkpoint inhibitors
CN121729429A (zh) 用一种或多种检查点抑制剂和toll样受体9激动剂的治疗有效组合治疗葡萄膜黑色素瘤肝转移的方法

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250321

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260327

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260327

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260327

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260327

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260331

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260331

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260401